Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) FCF Margin (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of FCF Margin readings, the most recent being 7.15% for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 1625.0% year-over-year to 7.15%, compared with a TTM value of 4.48% through Dec 2025, up 1578.0%, and an annual FY2025 reading of 4.48%, up 1578.0% over the prior year.
  • FCF Margin hit 7.15% in Q4 2025 for Apellis Pharmaceuticals, down from 23.62% in the prior quarter.
  • The five-year high for FCF Margin was 23.62% in Q3 2025, with the low at 20695.99% in Q2 2021.
  • Median FCF Margin over the past 5 years was 153.2% (2023), compared with a mean of 1446.16%.
  • The largest YoY upside for FCF Margin was 2003789bps in 2022 against a maximum downside of -43816bps in 2022.
  • Year by year, FCF Margin stood at 186.63% in 2021, then tumbled by -235bps to 624.78% in 2022, then skyrocketed by 89bps to 66.93% in 2023, then skyrocketed by 114bps to 9.1% in 2024, then crashed by -179bps to 7.15% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 7.15%, 23.62%, and 2.46% for Q4 2025, Q3 2025, and Q2 2025 respectively.